Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Metals One

    MCap

    —

    Last close

    GBP0.01

    ▲ 0.18 (19.44%)

    Endeavour Silver

    MCap

    CAD4,487m

    Last close

    CAD15.15

    ▲ 1.73 (12.89%)

    The Platform Group

    MCap

    EUR21m

    Last close

    EUR1.00

    ▲ 0.11 (12.61%)

  • Sectors

    Sectors

  • Megatrends

    Megatrends

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Sparks commentary - Herantis Pharma

Healthcare

Sparks - Herantis Pharma

More on this equity
Herantis Pharma (HEL: HRTIS) – Phase II preparations take centre stage (H126 results)
Published by Arron Aatkar, PhD

Herantis’s H126 results reflect continued progress towards the planned Phase II study of HER-096 in Parkinson’s disease, supported by positive FDA feedback and the integration of Indivi’s digital biomarker platform. The company expects to initiate the c 100-patient study in H127, subject to completion of remaining chemistry, manufacturing and controls (CMC) activities, regulatory approvals and additional financing. R&D expenses declined to €1.6m (from €2.0m in H125), while the net loss was broadly stable at €3.3m (H125: €3.2m). Herantis ended June with €3.5m in cash and short-term securities, with existing resources expected to fund CMC and clinical preparations through end-H127, although further capital will be required to launch Phase II. The €8m Horizon Europe grant and remaining European Innovation Council Fund capacity provide support, while partnering and additional financing remain key priorities ahead of study initiation.

Next Sparks Commentary in this sector >

Latest

Healthcare | Comment

Mendus (OMX: IMMU) – CML momentum builds (Q226 results)

Healthcare | Comment

SynAct Pharma’s (STO:SYNACT) Q226 results highlight resomelagon progress

Healthcare | Comment

Percheron Therapeutics (ASX:PER) FY26 results broadly in line, HMBD-002 in Focus

Healthcare | Comment

Zelluna (OSE: ZLNA) clears first safety hurdle in ZIMA-101

Financials | Comment

Halyk Bank reports Q226 results
Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.